Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Arcturus Therapeutics announced encouraging preliminary Phase II data for its ARCT-810 program for OTC deficiency, showing normal ammonia levels and reduced glutamine in participants with mild to moderate adverse events. The company also introduced LUNAR 2.0, a new delivery platform offering significantly higher protein expression, which will be incorporated into ARCT-2601 for potential lower doses and shorter infusions. Arcturus plans a Phase II/III pediatric trial in late 2027 and is expanding its preclinical mRNA programs for PKU and gout, alongside acquiring computational immunology company myNEO.
Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ)
Citi has upgraded Arcturus Therapeutics (ARCT) stock to Buy from Neutral following positive mid-stage trial data for its experimental liver disease drug, ARCT-810. Analyst Yigal Nochomovitz cited the promising results for the messenger RNA therapy designed to treat ornithine transcarbamylase deficiency.
Arcturus Therapeutics Releases ARCT-810 Phase 2 Clinical Results and mRNA Platform Update
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has announced the presentation of Phase 2 clinical trial data for its ARCT-810 candidate and provided an update on its mRNA delivery platform. This information was disclosed via a Form 8-K filing on September 23, 2026, which included a presentation and a press release summarizing the data. The filing ensures compliance with Regulation FD, mandating broad disclosure of material nonpublic information.
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency, demonstrating safety and efficacy in managing key biomarkers. The company also introduced LUNAR 2.0™, a next-generation mRNA delivery platform showing significantly higher protein expression, which will be used for ARCT-2601, a new therapeutic candidate for OTC deficiency. Additionally, Arcturus plans to acquire myNEO, an AI discovery company, to enhance mRNA design and target identification capabilities.
Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8
Citigroup has upgraded Arcturus Therapeutics (ARCT) to a "Buy" rating from "Neutral," also increasing its price target to $20 from $8. The article notes that Arcturus Therapeutics has an average rating of "buy" and a mean price target of $23.20. The full details of this analysis are available to premium subscribers.
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency, showing it was generally safe and well-tolerated while improving key biomarkers. The company also introduced LUNAR 2.0™, a next-generation mRNA delivery platform demonstrating significantly higher protein expression, and plans to integrate ARCT-2601, utilizing LUNAR 2.0™, into the ongoing Phase 2 study. Additionally, Arcturus will acquire myNEO, an AI discovery company, to enhance mRNA design and target identification capabilities.
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics will host a virtual presentation on September 23, 2026, to discuss Phase 2 clinical data for ARCT-810, their mRNA therapeutic for Ornithine transcarbamylase (OTC) deficiency, and provide an update on their mRNA liver therapeutics platform. Dr. Marshall Summar, an expert in rare diseases and OTC deficiency, will participate. ARCT-810 aims to restore functional OTC enzyme in the liver to address this life-threatening metabolic disorder.
ARCT Stock Price and Chart — NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) is a late-stage clinical mRNA medicines and vaccine company focusing on infectious diseases and rare conditions. Recent updates include dosing for ARCT-2601 in OTC deficiency patients and an upgrade to "Buy" by Citi after positive Phase 2 data for ARCT-810. The stock has shown significant volatility, with recent price decreases, but analysts have a wide forecast range.
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead
Arcturus Therapeutics presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting its pipeline with three key programs: an OTC deficiency therapy, an inhaled cystic fibrosis treatment, and a self-amplifying mRNA platform. The company anticipates several critical data readouts and decisions, including Phase II data for its OTC deficiency program and a Q4 decision on its cystic fibrosis treatment, which could unlock significant funding. Arcturus emphasized its differentiated technology, strong safety profiles, and strategic partnerships as it aims to address unmet medical needs and generate non-dilutive funding.
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Arcturus Therapeutics announced its participation in several investor conferences in September 2026, including the Wells Fargo, Citi's, Cantor Fitzgerald, H.C. Wainwright, and ROTH conferences. The company, a messenger RNA medicines company, will present on its pipeline and technologies, including its LUNAR® and STARR® platforms. Interested parties can find webcast links for these events on the Investor Relations/Events section of Arcturus’ website.
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Arcturus Therapeutics Holdings Inc. announced its participation in several upcoming investor conferences in September 2026, including events hosted by Wells Fargo, Citi, Cantor Fitzgerald, H.C. Wainwright, and ROTH. The company, a messenger RNA medicines developer, will engage in fireside chats, presentations, and investor meetings to discuss its focus on liver and respiratory rare disease therapeutics.
Arcturus Therapeutics (ARCT) Short Interest & Short Float | Updated Sep 2026
Arcturus Therapeutics (ARCT) reported a short interest of 6.53 million shares as of August 14, 2026, representing 27.93% of its public float, a decrease of 9.45% from the prior report. The short interest ratio is 9.9 days to cover, indicating a high level of pessimism among investors. Short interest has fluctuated significantly over the past year, with the highest percentage of float shorted reaching 38.3% in November 2025.
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ
Arcturus Therapeutics Holdings Inc. (ARCT) saw a significant price increase of 23.12%, adding $2.54 to its stock value. The article provides live quotes and charts for ARCT but notes that there is no current analyst rating data or earnings information available for the company. It also includes disclaimers about investment risks and the informational nature of the content.
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows
Arcturus Therapeutics stock (ARCT) surged nearly 20% due to positive sentiment surrounding its mRNA pipeline, including the regaining of global rights to its KOSTAIVE vaccine and a growing cash reserve of $191.5 million. Despite a slight revenue miss and continued losses in Q2, the company's strong balance sheet and advancing Phase 2 trials for ARCT-032 and ARCT-810 are providing catalysts for traders. Analysts maintain a "Buy" rating, seeing the recent collaboration changes and cash injection as beneficial for the company's future.
Liquidity Mapping Around (ARCT) Price Events
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a significant risk-reward short setup and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for ARCT.
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial health and potential need for future funding.
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase III in the fourth quarter, based on ongoing Phase II data. Additionally, Arcturus anticipates reporting data and regulatory updates for its injectable mRNA therapy for OTC deficiency (ARCT-810) before September 30, while maintaining a cash runway through 2028.
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9
H.C. Wainwright has reiterated its Hold rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $9. This indicates that the firm sees the stock as likely to perform in line with the broader market and does not anticipate significant price movement from current levels.
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23
BTIG has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its price target at $23. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen
Wall Street Zen upgraded Arcturus Therapeutics (ARCT) from "strong sell" to "sell," while Weiss Ratings maintained its "sell (D-)" rating. Despite these downgrades, MarketBeat's analyst consensus remains a "Moderate Buy" with an average price target of $24.25. The clinical-stage biotech company, which develops mRNA medicines and vaccines, reported a quarterly loss of $0.84 per share, beating expectations, but revenue of $2.96 million missed estimates.
Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS
Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE vaccine portfolio after ending a collaboration with CSL. Despite a sharp decline in revenue and cash, the company states it has sufficient cash runway through 2028.
Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside
Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains a "Buy," with 10 recommending Buy, 3 Hold, and 0 Sell. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20
CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics announced progress in its Q2 earnings call for 2026, advancing its rare-disease pipeline, completing enrollment for its Phase II OTC deficiency study, and regaining global rights to its KOSTAIVE COVID-19 vaccine and mRNA platform. The company also reported on its cystic fibrosis treatment candidate, ARCT-032, and its financial position, including cash and cash equivalents of $191.5 million as of June 30. Revenue decreased due to the end of the CSL collaboration, but the company's cash runway extends through the end of 2028.
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVE® and its infectious disease vaccine portfolio, receiving $12 million in cash and $16 million in released liabilities. Despite a decrease in revenue compared to the previous year, Arcturus maintains a strong cash position with a runway through 2028, supported by strategic collaborations and a focus on rare disease programs.
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view
Arcturus Therapeutics reported a narrower-than-expected loss for Q2 2026, beating EPS forecasts by 20%, but saw a significant revenue drop due to the conclusion of its CSL Seqirus collaboration. The company emphasized progress in its rare disease pipeline, including cystic fibrosis (ARCT-032) and ornithine transcarbamylase deficiency (ARCT-810) programs, with key clinical milestones expected later in 2026. Arcturus also regained global rights to its KOSTAIVE COVID-19 vaccine and broader self-amplifying mRNA platform, exploring new commercialization and partnering opportunities.
Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary
Arcturus Therapeutics Holdings Inc. (ARCT) reported its Q2 2026 financial results, with revenue of $2.96 million and a net loss of $23.79 million, resulting in a diluted loss per share of $(0.84). This decline in revenue is attributed to KOSTAIVE transitioning to commercial stages, leading to a significant drop in collaboration and grant revenue. Despite the financial decline, the company highlighted product momentum with KOSTAIVE's approval in Japan, ongoing clinical progress for ARCT-032 and ARCT-810, and strategic manufacturing partnerships.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) reported a Q2 loss of $0.84 per share, surpassing the Zacks Consensus Estimate of a $1.07 loss, and beat revenue estimates with $2.96 million. Despite underperforming the S&P 500 year-to-date, the company has exceeded EPS estimates in three of the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the market.
Why (ARCT) Price Action Is Critical for Tactical Trading
The article discusses the critical price action for Arcturus Therapeutics Holdings Inc. (ARCT) for tactical trading, highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 394.0:1 risk-reward setup targeting a 90.6% gain versus 0.2% risk and provides three distinct institutional trading strategies based on AI models: Position, Momentum Breakout, and Risk Hedging. The analysis also includes a multi-timeframe signal analysis indicating support and resistance levels across different time horizons.
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview
Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 100 cents per share in its upcoming earnings. This forecast is part of an earnings preview, suggesting investors and analysts are closely watching the company's financial performance. The full article provides more in-depth analysis from Reuters, accessible through a TradingView subscription.
Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Arcturus Therapeutics Holdings Inc (ARCT), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, its beta value compared to the S&P 500 index, and various financial metrics such as maximum drawdown, volatility, and liquidity. The assessment indicates that ARCT tends to outperform during upward markets but experiences larger declines during downward trends.
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its second-quarter financial results for 2026 on Thursday, August 6th, after market close. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide a corporate update. Arcturus is a messenger RNA medicines company focusing on liver and respiratory rare disease therapeutics, known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine.
Arcturus Therapeutics Q2 Results: Financials and update due Aug 6
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is scheduled to release its Q2 2026 financial results after market close on August 6, 2026, followed by a conference call at 4:30 p.m. ET for a corporate update. While no specific financial figures are in the pre-announcement, the call will cover the company's mRNA pipeline for rare diseases and pandemic vaccines. Investors can access the call via phone or webcast to gain insights into the company's strategic direction and therapeutic candidates.
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its second-quarter 2026 financial results after market close on Thursday, August 6th, and will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time. The company, a messenger RNA medicines focused on rare disease therapeutics, will also provide a corporate update during the event.
Arcturus Therapeutics Market Sentiment
This article provides an overview of market sentiment for Arcturus Therapeutics (ARCT), including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly higher than the current price, despite rising short interest. The report also highlights recent analyst actions and significant whale alerts related to the company.
Arcturus Therapeutics Holdings Inc
This article provides details on Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also offers general information about TradingKey's services and disclaimers regarding financial advice.
Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow
This article provides a detailed cash flow statement for Arcturus Therapeutics Holdings Inc (ARCT), covering quarterly and annual data from FY2012Q3 to FY2026Q1. It breaks down operating, investing, and financing cash flows, along with specific components like capital expenditures and changes in working capital. The detailed financial data helps evaluate the company's financial health and stability.
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT) focusing on its dividend and stock split history. It states that the company has not distributed dividends over the past five years. Key financial data like market capitalization and recent stock performance are also included.
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing its major shareholders and institutional holdings. Key shareholders include Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust Company, N.A., alongside data on institutional shareholding trends over recent quarters. The report also highlights ARCT's presence in various related ETFs.
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Arcturus Therapeutics Holdings Inc. (ARCT) on NASDAQ, showing its current stock price and performance. It indicates that Arcturus Therapeutics' stock is down by 4.84% at $5.79, with delayed prices. The page also presents a lack of current data for analyst ratings and earnings for ARCT.
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260
This article provides a financial summary of Arcturus Therapeutics Holdings Inc (ARCT), detailing its latest earnings report from May 7, 2026, and presenting historical quarterly and annual financial metrics. It covers key indicators such as EPS, revenue, net profit, various margins, and balance sheet items like assets, liabilities, and equity, offering an all-in-one data dashboard for investors. The article also includes frequently asked questions regarding the company's financial performance.
Arcturus Therapeutics Holdings Inc. Revenue Breakdown – NASDAQ:ARCT
This article provides a revenue breakdown for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). Last year, the company generated $82.03 million USD, primarily from its Messenger Ribonucleic Acid Medicines segment, and the largest contribution came from the United States. This marks a decrease from $152.31 million USD in the previous year.
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260
Arcturus Therapeutics Holdings Inc. (ARCT) closed at $5.530, down 4.49%. The company, focused on mRNA medicines and vaccines, has healthy fundamentals and significant growth potential, although its stock price has performed weakly recently. Analysts have given the stock an overall "Buy" rating with a target price of $19.89.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings, Actual EPS, EPS Estimates & Results
This article provides detailed earnings information for Arcturus Therapeutics Holdings Inc (ARCT), including its upcoming Q2 '26 earnings report, estimated EPS and revenue, and historical quarterly earnings data. It highlights past performance against estimates, showing both beats and misses. Additionally, the article includes recent news and trending discussions related to ARCT and other stocks.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, a messenger RNA medicines specialist, focuses on developing therapeutics for liver and respiratory rare diseases using its LUNAR®, STARR® mRNA technologies, and manufacturing expertise. Arcturus has a significant patent portfolio and collaborations, including one with CSL Seqirus and U.S. BARDA.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, an mRNA medicines developer, specializes in liver and respiratory rare disease therapeutics using LUNAR lipid-mediated delivery and STARR mRNA technology. Arcturus has a diverse pipeline including candidates for cystic fibrosis and ornithine transcarbamylase deficiency, in addition to partnered vaccine programs.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, focused on messenger RNA medicines for liver and respiratory rare diseases, will participate in a fireside chat. Arcturus is known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine, and has a robust pipeline including collaborations for pandemic flu and various RNA therapeutic candidates.
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20
Roth MKM has reiterated its Buy rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $20. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Arcturus Therapeutics Holdings Inc (ARCT), focusing on its price momentum, support and resistance levels, and key indicators. It highlights that ARCT's price momentum score is 4.35, placing it low within its industry, and the stock is trading between resistance at $7.68 and support at $5.69. The analysis of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages (MA5 to MA200) overwhelmingly suggests a "Sell" signal for the stock.
Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis
Arcturus Therapeutics (ARCT) is gaining attention for its inhaled mRNA therapeutic, ARCT-032, for cystic fibrosis, which is advancing to a pivotal Phase 2 study after promising early safety and mucus reduction data. The company has a robust mRNA platform, including self-amplifying mRNA and LUNAR® delivery, validated by the UK-approved COVID-19 vaccine, KOSTAIVE®. Despite being a high-risk, high-reward biotech play with a significant projected upside from Wall Street analysts, investors need to consider the inherent volatility and risks associated with clinical-stage biotech investments.
